Compare BATRA & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BATRA | HCM |
|---|---|---|
| Founded | 1991 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | 1811 |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.4B |
| IPO Year | N/A | N/A |
| Metric | BATRA | HCM |
|---|---|---|
| Price | $47.25 | $13.89 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 2 | 1 |
| Target Price | ★ $57.00 | $13.75 |
| AVG Volume (30 Days) | ★ 48.9K | 19.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.40 | $28.37 |
| Revenue Next Year | $8.54 | $17.50 |
| P/E Ratio | ★ N/A | $5.49 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $38.67 | $11.51 |
| 52 Week High | $50.45 | $19.50 |
| Indicator | BATRA | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 53.94 | 43.61 |
| Support Level | $45.81 | $13.09 |
| Resistance Level | $48.05 | $15.49 |
| Average True Range (ATR) | 1.32 | 0.45 |
| MACD | -0.27 | -0.02 |
| Stochastic Oscillator | 34.79 | 41.59 |
Atlanta Braves Holdings Inc is a holding company. It operates through its wholly-owned subsidiary, which is the owner and operator of the Atlanta Braves Major League Baseball Club and the mixed-use real estate development, The Battery Atlanta, and is the operator of the Atlanta Braves Major League Baseball Club's stadium, Truist Park. The company predominantly derives revenue related to the Braves baseball franchise and Truist Park from ticket sales, concessions, local broadcasting rights, advertising sponsorships, suites and premium seat fees, retail and licensing revenue, shared MLB revenue streams, including national broadcasting rights and licensing, and other sources. The company's reportable segments include: Baseball which generates key revenue, and Mixed-Use Development.
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.